Fu Alex Z, Li Zhiyi, Tang Jackson, Mahmood Syed, Whisman Tyler, Qiu Ying
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
Asclepius Analytics LLC, New York, NY 10004, USA.
J Comp Eff Res. 2018 Sep;7(9):867-879. doi: 10.2217/cer-2018-0022. Epub 2018 Sep 7.
To determine the costs of adverse events (AEs) associated with current metastatic melanoma (MM) therapies.
MATERIALS & METHODS: Two retrospective cohort studies were independently conducted using the PharMetrics and MarketScan databases. Included patients were aged ≥18 years, and had ≥1 MM diagnosis and ≥1 claim for systemic therapy from 2004 to 2015.
A total of 1654 and 1329 patients were identified in PharMetrics and MarketScan, respectively. The corresponding adjusted 30-day incremental costs of AEs by category were highest for CNS/psychiatric (US$21,277 and $18,739), gastrointestinal ($18,534 and $15,648), respiratory ($17,338 and $17,064), cardiovascular ($16,083 and $15,430), hematological/lymphatic ($14,997 and $15,538) and metabolic/nutritional AEs ($12,340 and $17,251).
The costs of AEs associated with systemic therapies for MM are substantial.
确定与当前转移性黑色素瘤（MM）治疗相关的不良事件（AE）成本。
使用PharMetrics和MarketScan数据库独立开展两项回顾性队列研究。纳入患者年龄≥18岁，在2004年至2015年期间有≥1次MM诊断且有≥1次全身治疗索赔记录。
在PharMetrics和MarketScan中分别识别出1654例和1329例患者。按类别划分的不良事件相应调整后30天增量成本，中枢神经系统/精神方面最高（21,277美元和18,739美元），其次是胃肠道（18,534美元和15,648美元）、呼吸系统（17,338美元和17,064美元）、心血管系统（16,083美元和15,430美元）、血液学/淋巴系统（14,997美元和15,538美元）以及代谢/营养方面的不良事件（12,340美元和17,251美元）。
与MM全身治疗相关的不良事件成本很高。
